Innate Pharma receives regulatory authorization to start randomized Phase II trial with IPH2102 in Acute Myeloid Leukemia
Signing of a liquidity contract with GILBERT DUPONT, ending of the previous liquidity contract with NATIXIS SECURITIES
Number of shares and voting rights of Innate Pharma as at July 1, 2012
All proposed resolutions at the Annual General Meeting of June 28, 2012 were voted according to management’s recommendations
Innate Pharma to hold its Annual General Meeting of Shareholders on June 28, 2012, in Marseilles, France
“Immunology and Innate Immunity are Keys to Cancer Treatment” Conclusions of the Roundtable of internationally renowned speakers, including winners of the 2011 Nobel Prize in Medicine
Innate Pharma announces its revenue for the first quarter of 2012 and updates on its cash position
World Leading Innate Immunity Specialists to Convene for Roundtable Discussion: "Innate immunity: from revolutionary discovery to revolution in therapy" - May 15, 2012, in Paris
2011 full year results: a year of momentum for Innate Pharma
Innate pharma reports higher annual revenue in 2011
